Quadruple Myelitis – A Complete Patient‑Friendly Guide

Overview

Quadruple myelitis is an extremely rare inflammatory condition that simultaneously involves four distinct segments of the spinal cord. The term “myelitis” refers to inflammation of the spinal cord; when four separate areas are affected, clinicians use the descriptor “quadruple.” The disease can cause a combination of motor, sensory, and autonomic dysfunctions depending on which spinal levels are involved.

• Who it affects: Adults between 20–55 years are most frequently diagnosed, with a slight male predominance (≈ 55 % male). Cases in children and older adults have been reported, but they are uncommon.
• Prevalence: Exact prevalence is unknown because the condition is rare and often grouped with transverse myelitis in epidemiologic studies. Estimates suggest < 1 case per 1 million people annually worldwide, making it a “rare disease” by U.S. standards (≤ 200,000 affected individuals).^{[1] NIH Rare Diseases Information Center}
• Prognosis: Outcomes vary widely; early treatment improves recovery, but many patients experience residual weakness or sensory loss.

Symptoms

Symptoms reflect the level(s) of the spinal cord that are inflamed. Because four segments are involved, patients often have a mix of signs that may appear simultaneously or sequentially.

Neurological Symptoms

• Motor weakness: Varying degrees of paresis or paralysis in the limbs corresponding to the affected spinal levels.
• Spasticity: Involuntary muscle tightness, especially in the legs.
• Hyperreflexia: Exaggerated deep tendon reflexes.
• Ataxia: Uncoordinated gait or difficulty with fine motor tasks.

Sensory Symptoms

• Pain: Sharp, burning, or aching pain that may radiate along dermatomes.
• Numbness or tingling: “Pins‑and‑needles” sensations below the level of inflammation.
• Loss of proprioception: Difficulty sensing limb position, leading to balance problems.

Autonomic Symptoms

• Bladder dysfunction: Urinary urgency, retention, or incontinence.
• Bowel dysfunction: Constipation or loss of control.
• Sphincteric issues: Sexual dysfunction, especially erectile dysfunction in men or decreased lubrication in women.

Systemic Symptoms

• Fever, chills, or recent viral illness (often precedes onset).
• Headache or visual disturbances if an associated autoimmune process (e.g., neuromyelitis optica) is present.

Causes and Risk Factors

Quadruple myelitis is not a single disease entity but a manifestation of various underlying processes that cause widespread spinal inflammation.

Immune‑Mediated Causes

• Neuromyelitis optica spectrum disorder (NMOSD): Autoantibodies (AQP4‑IgG) attack astrocytes, leading to longitudinally extensive myelitis that can involve multiple non‑contiguous segments.
• Multiple sclerosis (MS): Although MS typically produces discrete lesions, rare cases show multifocal spinal involvement.
• Acute disseminated encephalomyelitis (ADEM): Post‑infectious demyelination that can involve several spinal levels.

Infectious Triggers

• Viral: West Nile virus, herpes simplex, varicella‑zoster, Epstein‑Barr, and SARS‑CoV‑2 have been reported to precipitate extensive myelitis.
• Bacterial: Mycoplasma pneumoniae, Borrelia burgdorferi (Lyme disease), and Tuberculosis (Pott disease) occasionally involve the spinal cord.
• Parasitic: Rarely, schistosomiasis or neurocysticercosis can cause multi‑segmental inflammation.

Other Etiologies

• Paraneoplastic syndromes: Autoimmune response to a hidden malignancy (e.g., lung or breast cancer).
• Vascular: Spinal cord infarction or vasculitis can mimic inflammatory lesions.
• Medication‑related: Rare adverse reactions to immune checkpoint inhibitors or certain antibiotics.

Risk Factors

• Recent infection or vaccination (temporal association, not causation).
• Pre‑existing autoimmune disease (e.g., systemic lupus erythematosus, Sjögren’s syndrome).
• Genetic susceptibility – certain HLA haplotypes (e.g., HLA‑DRB1*03) have been linked to NMOSD.
• Age 20‑55 years and female sex for NMOSD‑related myelitis; male predominance for post‑infectious forms.

Diagnosis

Because quadruple myelitis can mimic other spinal cord disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed history (onset, preceding illness, exposure, autoimmune background).
• Comprehensive neurological exam documenting motor strength, sensation, reflexes, and autonomic function.

Imaging

• MRI of the spine (with and without gadolinium): The gold standard. Look for ≥ 3 non‑contiguous hyperintense T2 lesions spanning at least four vertebral segments. Gadolinium enhancement indicates active inflammation.^{[2] Mayo Clinic}
• Brain MRI to assess for concurrent demyelinating plaques (helps differentiate MS from NMOSD).

Laboratory Tests

• Serum autoantibodies: AQP4‑IgG and MOG‑IgG (myelin oligodendrocyte glycoprotein) panels.
• Inflammatory markers (ESR, CRP) – may be modestly elevated.
• Infectious work‑up: PCR or serology for HSV, VZV, West Nile, SARS‑CoV‑2, Borrelia, etc., based on exposure history.
• Lumbar puncture (CSF analysis):
• Elevated protein, mild pleocytosis (usually < 100 cells/µL).
• Oligoclonal bands – suggest MS if present; absent in many NMOSD cases.

Other Specialized Tests

• Visual evoked potentials (VEP) if optic neuritis is suspected.
• Somatosensory evoked potentials (SSEP) to assess conduction across the spinal cord.

Diagnostic Criteria

Current consensus (International Panel for NMOSD) defines “longitudinally extensive transverse myelitis (LETM)” as a lesion ≥ 3 vertebral segments. Quadruple myelitis meets this definition plus the presence of at least two additional non‑contiguous lesions, confirmed by MRI and supported by clinical‑laboratory correlation.

Treatment Options

Therapy is aimed at halting inflammation, preventing permanent damage, and managing symptoms.

Acute Phase – High‑Dose Corticosteroids

• Methylprednisolone 1 g IV daily for 3‑5 days, followed by an oral taper.
• Most patients experience rapid pain relief and stabilization of neurological decline.

Plasma Exchange (PLEX)

• Indicated when steroids fail or in severe NMOSD attacks.
• 5‑7 exchanges over 10‑14 days have shown 60‑70 % improvement in neurologic scores.^{[3] Cleveland Clinic}

Immunosuppressive Maintenance

Long‑term therapy reduces relapse risk.

• Aquaporin‑4 (AQP4) positive NMOSD: Rituximab (375 mg/m² weekly × 2, then every 6 months), Mycophenolate mofetil 1‑2 g/day, or Azathioprine 2‑3 mg/kg/day.
• MOG‑IgG disease: Similar agents; some patients respond to oral steroids alone.
• Post‑infectious or ADEM‑related myelitis: Short taper of steroids; most do not need chronic immunosuppression.

Symptomatic Management

• Pain: Gabapentin, Pregabalin, or Tricyclic antidepressants.
• Spasticity: Baclofen (oral or intrathecal pump), Tizanidine.
• Bladder dysfunction: Intermittent catheterization, anticholinergic agents (Oxybutynin), or clean intermittent self‑catheterization training.
• Depression/Anxiety: Counseling, SSRIs, or CBT as needed.

Rehabilitation & Lifestyle

• Physical therapy (strengthening, gait training).
• Occupational therapy (adaptive equipment, ADL strategies).
• Regular aerobic activity within tolerance – improves fatigue and mood.

Living with Quadruple Myelitis

Adapting daily life is crucial for independence and quality of life.

Mobility Aids

• Canes, quad‑cane, or walkers for mild weakness.
• Wheelchairs (manual or power) for severe lower‑extremity paresis.
• Home modifications – grab bars, wheelchair‑friendly bathroom, stair lifts.

Bladder & Bowel Management

• Schedule voiding every 2‑3 hours; keep a diary.
• Stay hydrated; avoid caffeine and alcohol if they irritate the bladder.
• Consider a referral to a urologist for catheter training or sacral nerve stimulation.

Fatigue Management

• Plan activity bursts with scheduled rest.
• Use energy‑conservation techniques – sit while cooking, keep frequently used items within reach.
• Assess for sleep apnea or vitamin D deficiency, which can worsen fatigue.

Psychosocial Support

• Join support groups (e.g., NMOSD Foundation, MS Society).
• Seek counseling early; chronic illness often triggers depression.
• Educate family and caregivers about signs of relapse.

Regular Follow‑up

• Neurology visits every 3‑6 months or sooner after a flare.
• Annual MRI of the spine (and brain if indicated) to monitor lesion activity.
• Blood work to monitor immunosuppressant levels and organ function.

Prevention

Because many triggers are unavoidable, focus on modifiable risk factors.

• Vaccination: Keep routine vaccines up‑to‑date (influenza, COVID‑19). Some data suggest that infections, not vaccines, precipitate myelitis.
• Prompt treatment of infections: Early antiviral or antibiotic therapy can reduce the risk of post‑infectious inflammatory complications.
• Autoimmune disease control: Adequate management of conditions such as lupus or sarcoidosis lowers the chance of secondary myelitis.
• Healthy lifestyle: Regular exercise, balanced diet, and stress reduction support immune regulation.
• Medication vigilance: Discuss any new drug (especially immune checkpoint inhibitors) with your neurologist.

Complications

If inflammation is not promptly controlled, permanent spinal cord damage can occur.

• Persistent motor deficit: Chronic weakness or paralysis.
• Severe spasticity: May require intrathecal baclofen pumps.
• Chronic pain syndromes: Neuropathic pain resistant to first‑line agents.
• Neurogenic bladder: Recurrent urinary tract infections, kidney damage.
• Deep vein thrombosis (DVT): Reduced mobility increases clot risk.
• Psychiatric disorders: Depression, anxiety, and cognitive slowing.
• Relapse/Recurrent myelitis: Up to 30 % of NMOSD patients experience another attack within 5 years if untreated.^{[4] CDC}

When to Seek Emergency Care

---

References

1. National Institutes of Health – Rare Diseases Information Center. “Myelitis, Transverse.” Accessed June 2024.
2. Mayo Clinic. “Transverse Myelitis: Symptoms and Causes.” Updated 2023.
3. Cleveland Clinic. “Plasma Exchange Therapy for Neuromyelitis Optica.” 2022.
4. Centers for Disease Control and Prevention. “Neuromyelitis Optica Spectrum Disorder (NMOSD).” 2023.